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Abstract The assessment of proarrhythmic risks of drugs
remains challenging. To evaluate the suitability of rat
engineered heart tissue (EHT) for detecting proarrhythmic
effects. We monitored drug effects on spontaneous con-
tractile activity and, in selected cases, on action potentials
(sharp microelectrode) and Ca2? transients (Fura-2) and
contraction under electrical pacing. The Ito-blocker inhib-
itor 4-aminopyridine increased action potential duration
and T2 and caused aftercontractions, which were abolished
by inhibitors of ryanodine receptors (RyR2; JTV-519) or
sodium calcium exchanger (NCX; SEA0400). 77 Drugs
were then tested at 1-10-1009 free therapeutic plasma
concentrations (FTPC): Inhibitors of IKr, IKs, Ito, antiar-
rhythmics (8), drugs withdrawn from market for torsades
des pointes arrhythmias (TdP, 5), drugs with measurable
(7) or isolated TdP incidence (13), drugs considered safe
(14), 28 new chemical entities (NCE). Inhibitors of IKr or
IKs had no effect alone, but substantially prolonged relax-
ation time (T2) when combined at high concentration.
15/33 drugs associated with TdP and 6/14 drugs considered
non-torsadogenic (cibenzoline, diltiazem, ebastine, keto-
conazole, moxifloxacin, and phenytoin) induced concen-
tration-dependent T2 prolongations (10-1009 FTPC).
Bepridil, desipramine, imipramine, thioridazine, and
erythromycin induced irregular beating. Three NCE pro-
longed T2, one reduced force. Drugs inhibiting repolari-
zation prolong relaxation in rat EHTs and cause
aftercontractions involving RyR2 and NCX. Insensitivity
to IKr inhibitors makes rat EHTs unsuitable as general
proarrhythmia screen, but favors detection of effects on Ito,
IKs ? Ito or IKs ? IKr. Screening a large panel of drugs
suggests that effects on these currents, in addition to IKr,
are more common than anticipated.
Keywords Arrhythmia  Torsades des pointes  Drugs 
In vitro screening  Engineered heart tissue
Introduction
Proarrhythmic side effects of drugs can be life-threatening
and have led to a number of drug withdrawals from the
market [17]. Predicting the arrhythmogenic potential in
preclinical drug development is difficult for several reasons
[25, 37]. (1) Mechanisms of arrhythmias are complex. This
is exemplified by the fact that not only loss-of-function, but
also gain-of-function mutations of K?- and Na?-channels
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can cause arrhythmias by promoting ectopic activity, dis-
persion, and/or re-entry circuits [1]. This corresponds with
clinical experiences that both class I (Na?-channel block-
ers) and class III (K?-channel blockers) antiarrhythmic
drugs have significant proarrhythmic effects [10]. In addi-
tion, dysfunction of the sarcoplasmic reticulum Ca2?-
release channel (RyR2) or the SR Ca2?-storage protein
calsequestrin underlie catecholaminergic polymorphic
ventricular tachycardia, characterized by increased ectopic
automaticity in situations of stress. (2) The heart is
equipped with several safety mechanisms, explaining why
one hit is rarely sufficient to cause symptomatic arrhyth-
mias. Even patients with inherited rhythm disorders expe-
rience clinically relevant arrhythmias relatively late in life
and/or only under certain trigger situations such as
increased sympathetic drive, hypokalemia, drugs, ischemia,
or myocardial scars. (3) The existing preclinical test sys-
tems have shortcomings [14, 25, 37]. In current routine,
new chemical entities (NCE) are tested on cells over-
expressing the human eag-related gene (hERG), and those
with significant inhibitory activity are excluded from fur-
ther development. Whereas hERG-tests have documented
high sensitivity and specificity for this single ion current
and the principal relevance for hERG-inhibition in causing
torsades des pointes (TdP) is undisputed, the predictive
value of this test is limited [21, 31]. Several drugs have
hERG-inhibitory activity without being associated with
TdP-arrhythmias (e.g., verapamil). Others have no relevant
hERG-activity at clinically used concentrations, but
increase the risk of arrhythmias (e.g., mefloquine and
phenytoin; [31]).
The Food and Drug Administration and the European
Medicines Agency currently recommend an integrated risk
assessment, which includes the results of several experi-
mental tests (e.g., hERG, rabbit Purkinje fibers, and dog
telemetry) as well as in silico and clinical data [11, 12, 38].
The content of current tests may be improved by charac-
terizing NCEs in a whole panel of cell lines, each
expressing a different cloned ion channel. This approach
provides a more comprehensive picture of a drugs channel-
affecting activity [3, 42], but needs modeling to predict the
integrated effect. An alternative strategy is to test drugs
directly on cardiac myocytes or more complex cardiac
tissues as the ‘‘real substrate’’ for arrhythmias, assuming
that any reproducible effect is relevant, independent of its
exact mechanism. Unfortunately, isolated adult cardiac
myocytes do not beat and, similar to Purkinje fibers or
Langendorff-perfused hearts, cannot be examined in large
series. Instrumented dogs or rabbits are the most valid
models, but cannot be used for screening large number of
NCEs, both for ethical and financial reasons.
We have recently developed an automated miniaturized
drug screening assay based on our EHT technology and
neonatal rat cardiac myocytes, which appears to combine
some of the advantages of a relatively intact 3D cardiac
tissue, availability at large numbers, robustness and high-
content readout, particularly analysis of contractile force
and kinetics [7, 16, 20]. Experiments with a limited number
of model compounds indicated assay sensitivity to detect
proarrhythmic effects of drugs [16]. The aim of the present
study was to systematically determine the predictive value
of the assay by testing a larger number of clinically used
compounds with characterized hERG-inhibitory activity
and proarrhythmic potential in humans [31] and randomly
picked NCEs as well as underlying mechanisms.
Materials and methods
The investigation conforms to the guide for the care and
use of laboratory animals published by the NIH (Publica-
tion No. 85-23, revised 1985). A detailed description of
methods can be found in the supplemental file.
Cell isolation and EHT-generation
Heart cells of postnatal d0–d3 Wistar rats and EHTs were
prepared as previously described [16, 44]. Fresh neonatal
heart cells were mixed with medium, fibrinogen and
thrombin, and casted into strip-format (12 9 3 9 3 mm)
molds in agarose, in which pairs of elastic silicone posts
were placed from above. EHTs maintained for up to
4 weeks.
Measurement of contractile parameters
Contractile parameters were evaluated as previously
described [16]. In principle, the 24-well-plates with EHTs
(14–21 days) were put in a gas-, temperature-, and humid-
ity-controlled incubator with glass roof and customized
software-controlled video camera placed on top. Contractile
parameters of spontaneously beating EHTs were evaluated
using an automated figure recognition algorithm. Deflection
of the silicone posts was recorded over time and, based on
post geometry and elastic modulus of the silicone, used to
calculate force, frequency, fractional shortening, contrac-
tion and relaxation time (bpm, T1 [from 20 % to peak] and
T2 [from peak to 20 %], respectively).
Drug screening—video optical analysis
All measurements were performed with 14–21 day old
EHTs in fresh serum-free DMEM (Biochrom F04115),
supplemented with 10 mM HEPES for pH-steadiness, pre-
incubated at 37 C, 40 % O2, 7 % CO2, 90 % humidity for
2 h. Measurements were done routinely 1 day after feeding
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with standard EHT medium. The drugs were analyzed in
three different concentrations (45 min each, cumulative,
1–1009 free therapeutic plasma concentration [FTPC]). For
drug details including solvents see Supplement Table 1.
Prior to each measurement, 50 nM epinephrine (Sigma
E4643) was added to each well to simulate ‘‘physiological’’
conditions and enhance the likelihood of contractile activity
within the 60 s recording time. Drugs were added under
sterile conditions. After 45 min incubation in a standard
incubator, EHTs were transferred to the video optical system
(Fig. 1). Due to a sequential mode of measurement (total
time *30 min), incubation time varied from the first to the
last EHT (45–75 min).
Measurements under perfusion and electrical
stimulation, Ca2?-transients, action potentials
Intracellular Ca2?-transients were analyzed in parallel with
force under electrical stimulation and continuous perfusion
using a novel setup as described previously [35]. The setup
consisted of an inverted microscope, a temperature- and
O2/CO2-controlled chamber for the 24-well EHT plate, a
flow rate-controlled perfusion system, platinum–iridium
wire electrodes for field stimulation, a fluorescence light
source (IonOptix Hyperswitch), a photomultiplier, video
cameras and software (both IonOptix) for the evaluation of
contractile activity (edge detection mode). Experiments
were done at 4 ml flow/min (per well) and 2–4 Hz stimu-
lation in modified Tyrode’s solution.
For Fura loading, EHTs were incubated in Tyrode’s
solution containing 10 lM Fura2-AM (Invitrogen F1221)
and Cremophor EL (0.75 %; Sigma C5135) for 2 h at
37 C. The ratio of light emission (510 nm) at excitation
with 340 and 380 nm light (F340/380 ratio) was used as an
index of cytosolic Ca2?-concentration.
Action potentials (APs) were recorded with standard
intracellular microelectrodes in intact EHTs. Bath solution
contained (in mM): NaCl 127, KCl 4.5, MgCl2 1.5, CaCl2
1.8, glucose 10, NaHCO3 22, NaHPO4 0.42, equilibrated
with O2-CO2 [95:5] at 36.5 ± 0.5 C, pH 7.4. Preparations
were field-stimulated for at least 1 h (2 Hz) before data
acquisition. APs were analyzed off-line using the Lab-
Chart software (ADInstruments, Spechbach, Germany).
Statistical analysis
Data were expressed as mean ± SEM. Statistical differ-
ences were analyzed using the one-way analysis of variance
(ANOVA) followed by the Dunett’s (all compared to base-
line) or Tukey’s (all compared to all) adjustment for post hoc
multiple comparison, or by paired or unpaired Student’s
t test, as indicated in the legend of each figure. Results were
considered statistically significant if a paired Student’s t test
revealed a p value of less than 0.05 and the deviation from
baseline was at least 15 %. This limit was defined after initial
series of experiments had shown that formally significant
(t test), but not concentration-dependent effects of drugs
often amounted to ±11 %. Further support for the 15 %
threshold came from quantifying the mean ± SD of all
baseline measurements (n = 221 independent EHTs), which
amounted to 99.6 ± 11.4 % (SEM ± 0.77 %).
Results
Mechanisms of twitch prolongation and irregular
beating pattern
In a previous study with EHTs, we found that the experi-




Fig. 1 Schematic illustration of the standard operation procedure for
evaluating drug effects. EHTs were subjected to measurements at day
14–21. One day before measurement culture medium was changed.
Before evaluation, EHTs were transferred to fresh, preincubated
(37 C, 7 % CO2, 40 % O2), serum-free DMEM supplemented with
10 mM HEPES for pH steadiness, and incubated for 45 min.
Epinephrine (50 nM) was added and contractile parameters were
analyzed by the video optical system. Thereafter, EHTs were
transferred to fresh preincubated DMEM, including HEPES plus the
first concentration of a drug, and incubated for 45 min. Epinephrine
was added, measurements were done and this circuit started again
with the second concentration of the drug
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to inhibit IKr and cause TdP in humans, quinidine and
erythromycin, caused concentration-dependent prolonga-
tions of relaxation time T2 [16]. These observations sug-
gested that T2 is a useful surrogate for drug-induced
prolongations of repolarization and proarrhythmic effects.
To test this hypothesis, we evaluated the effects of the Ito-
inhibitor 4-aminopyridine (4AP; IC50 on Ito in adult rat
ventricular myocytes: 980 lM [41]) on EHTs. 4AP pro-
longed T2 concentration dependently reaching significance
at 3 mM (Fig. 2). At 30 mM, EHTs showed extremely
prolonged relaxation (?502 %), comparable to what have
been seen previously with chromanol (?710 %; [16]).
Prolonged contractions can either be caused by altered
intracellular Ca2? transients or myofilament response to
Ca2?. To differentiate between these mechanisms, EHTs
were subjected to sharp electrode measurements of action
potentials and calcium transients (Fura-2; Fig. 3). Action
potential characteristics under basal conditions and elec-
trical stimulation were similar as described previously in
this model [16]. 4AP increased action potential duration
(APD90) from a mean of 113 to 175 ms (Fig. 3a, b). 4AP
also prolonged intracellular Ca2? transients, whereas the b-
adrenergic agonist epinephrine shortened it, both in the
absence and presence of 4AP (Fig. 3c–f). Quinidine, a still
prescribed drug for the treatment of atrial fibrillation, also
increased APD90 from 179 to 232 ms at 100 lM (Sup-
plemental Fig. 5d). These data supported the interpretation
that alterations in T2 reflect similar changes in APD and
the kinetics of intracellular Ca2? transients. Accordingly, a
high concentration of caffeine, known to open ryanodine
receptors (RyR2) in the sarcoplasmic reticulum (SR),
reduced beating rate and induced a large and wide twitch
(Supplemental Fig. 1).
4AP not only prolonged T2, but also induced beat-to-beat
irregularities, variations of twitch amplitude and aftercon-
tractions falling into the relaxation phase of prolonged
twitches (Fig. 4). To investigate the role of different cellular
effector systems in the T2-prolonging effect of repolariza-
tion-prolonging compounds, we determined the effect of
4AP in the absence and presence of tetrodotoxin (INa), tet-
racaine (INa), verapamil (ICa), thapsigargin (SERCA),









beating EHTs in the absence
(baseline, only epinephrine
50 nM) and presence of
increasing concentrations of
4AP. f statistical evaluation of
relaxation time (T2; each dot
represents one analyzed EHT;
**p \ 0.003, ***p \ 0.0001 vs.
baseline one-way ANOVA?
Dunnett’s post test). The
concentration of 4AP was
cumulatively increased with
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(RyR2), respectively. Verapamil had no discernible effect,
thapsigargin, tetrodotoxin and tetracaine all increased the
T2-prolonging effect of 4AP (Supplemental Fig. 2). In
contrast, SEA0400 and JTV519 reduced the effect of 4AP
(Fig. 4). Both compounds completely abolished beating
irregularity and aftercontractions, but only partially T2-
prolongation. T2 values were 127 (SEA ? 4AP) vs. 78 ms
(SEA alone) and 195 (JTV ? 4AP) vs. 80 ms (JTV alone).
This suggests that part of the 4AP-induced T2-prolongation
was a direct consequence of action potential prolongation,
whereas the SEA- and JTV-sensitive after contractions and
pronounced T2-prolongations were mediated by RyR2 and





Fig. 3 Effect of 4-aminopyridine (4AP; 10 mM), epinephrine
(50 nM) or their combination on action potential duration (APD90),
Fura-2 F340/380 ratio and relaxation time (T2) of electrically
stimulated EHTs (2 Hz). For APD90 measurements two independent
groups of EHTs (n = 3, each) were directly perfused with vehicle
control (VC) or 4-aminopyridine (4AP), electrically stimulated and
contractions recorded. Preparations were stimulated for at least 1 h
before drug exposure and data acquisition. For Fura-2 F340/380 ratio
and T2 the two independent groups (n = 8, each) were preincubated
with VC or 4AP. Thereafter, EHTs were perfused and electrically
stimulated (2 Hz; baseline) for 10 min, before epinephrine (50 nM)
was added to the perfusion system. a Average peaks for action
potentials in the absence (VC, black line) and presence of 4AP (red
line). b Statistical evaluation of APD90. c Original recordings of
F340/380 ratio transients in the absence (VC, left) and presence of
epinephrine (right). d Original recordings in the presence of 4AP
alone (left) and 4AP plus epinephrine (right). The red line displays the
unfiltered signal, whereas the blue line displays the filtered signal.
e Statistical evaluation of time to 90 % return of the F340/380 ratio
and F T2. Each point represents one EHT. *p \ 0.05, **p \ 0.003,
***p \ 0.0001, Student’s t test, paired for comparison within one
group (baseline vs. epinephrine) and unpaired for comparison
between the two groups (VC vs. 4AP); y-axes for C, D: F340/380
ratio in arbitrary units (AU). Note that 4AP increased T2 and time to
90 % return of the F340/380 ratio, both in the absence and presence of
epinephrine. Epinephrine alone shortened T2 and F340/380 transients.
Note also the failure of capture under 4AP
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Role of IKr and IKs in T2 prolongations
The role of IKr and IKs for action potential repolarization in
rat heart is still poorly understood [32]. We studied the
involvement of these two currents in rat EHTs by applying
the reference IKr blocker E-4031 (IC50 7.7 nM [43]) and
the selective IKs blocker HMR-1556 (IC50 10.5 nM [36])
alone or in combination (1–1,000 nM, Fig. 5). Neither
E-4031 nor HMR-1556 affected T2 even at high concen-
trations (1,000 nM). The combined application also did not
affect T2 at up to 100 nM, but caused a substantial increase
at 1,000 nM ([8-fold). Given the high selectivity of
E-4031 and HMR-1556 for IKr and IKs (HMR-1556 IC50 on
Ito: 33.9 lM; on ICa: 27.5 lM; on IKr: 12.6 lM [36]),
respectively, the effect of the combination suggests a role
of these two currents for determining the repolarization
reserve in rat EHTs.
Screening of proarrhythmic compounds
under spontaneous beating
To test the usefulness of our screening system for the
detection of proarrhythmic compounds, we analyzed a
large panel of drugs associated with arrhythmias. The
selection was made according to a list of drugs published
by Redfern and colleagues [31] which related various
levels of proarrhythmic risk with inhibition of IKr (hERG).
We tested the effect of the 46 compounds of this list which
were commercially available (details Supplemental
Table 1) at 1-, 10-, and 100-fold FTPC, n = 4–8 each. In
addition, we tested moxifloxacin, an important inhibitor of
bacterial gyrases, associated with prolongation of the QT-
interval, but not with arrhythmias [28]. The selection of
compounds encompassed 8 clinically used antiarrhythmic
drugs (Group I), 5 drugs withdrawn from the market for
TdP (Group II), 7 drugs with measurable incidence of TdP
in humans (Group III), 13 drugs with isolated reports of
TdP (Group IV) and 14 drugs devoid of TdP reports and
therefore considered safe (Group V; Figs. 6, 7). Under the
experimental conditions (which included a *EC50 [6]
epinephrine concentration, 50 nM) and in the absence of
interventional drugs, EHTs showed a typical and repro-
ducible beating pattern, consisting of periods with high
frequency (4.4–4.6 Hz, called ‘‘bursts’’, 8–10 s length) and
periods of contractile inactivity (30–40 s; Supplemental





Fig. 4 Effect of inhibitors of
the ryanodine-receptor (JTV519
2 lM) or the sodium calcium
exchanger (NCX, SEA0400
2 lM) on 4-aminopyridine
(4AP 10 mM)-induced
prolongations of relaxation and
aftercontractions in
spontaneously beating EHTs. a–
d Original recordings of the
contractile activity of EHT in
the absence of drugs (a,
c vehicle control), JTV519 (a,
JTV519), SEA0400 (c,
SEA0400), 4AP alone (b,
d vehicle control) or in the
presence of JTV519 (b,
JTV5019) or SEA0400 (d,
SEA0400). e, f Time course of
the effect of 4AP in the absence
(black dots) or presence of
JTV519 (e clear squares) or
SEA0400 (f clear squares).
n = 8; data are expressed as
mean ± SEM; *p \ 0.05,
**p \ 0.003, ***p \ 0.0001 vs.
vehicle control, one-way
ANOVA? Tukey’s post test.
Note that both inhibitors
prevented the marked 4AP-
induced T2 prolongation and
after contractions, but did not
completely normalize T2 or
beating frequency
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(SEM) T1 and T2 of 67 ± 8 (±1) and 92 ± 18 (±2) ms,
respectively. Given that the bursts occurred by chance
either fully inside the 60 s recording window or only par-
tially, the total number of beats per 60 s was relatively
meaningless. In contrast, the frequency of beating in the
burst was stable and systematically affected by epinephrine
(?15–20 %) and carbachol (reversed epinephrine effect
and induced partial stop; Supplemental Fig. 3).
Given our previous results with erythromycin and
quinidine [16], we focused on T1, T2, and the beating
pattern as possible surrogates for arrhythmias. A threshold
of 15 % T2 prolongation was considered significant (see
Statistics for details). Supplemental Fig. 4 depicts typical
examples of drug responses, Figs. 6 and 7 show the T2
effect of 47 drugs according to the Redfern classification.
Significant T2 prolongations were observed with 4/8
Redfern Class I drugs (antiarrhythmics; quinidine, diso-
pyramide, sotalol, procainamide; Fig. 6a), 1/5 drugs
withdrawn from the market due to TdP (Redfern Class II;
cisapride; Fig. 6b), 4/7 drugs with measurable incidence
of TdP (Redfern Class III; aprindine, bepridil, flecainide,
erythromycin; Fig. 6c), 6/13 drugs with isolated TdP
reports (Redfern Class IV; domperidone, sparfloxacin,
propafenone, desipramine, fexofenadine, clarithromycin;
Fig. 7a), and 6/14 drugs considered safe (ebastine,
ketoconazole, diltiazem, cibenzoline, phenytoin, moxi-
floxacin; Fig. 7b). Whereas most drugs prolonged T2 only
at 1009 FTPC, phenytoin exerted this effect already at
19 FTPC. In addition, five compounds (bepridil, desi-
pramine, imipramine, thioridazine, and erythromycin)
induced irregular beating as the primary effect, charac-
terized by a ‘‘sinusoidal’’ fluctuation of twitch amplitudes
(Supplemental Fig. 4a). The effect was time dependent
and was followed by complete stop of beating. It occurred
at concentrations of 30–100 fold FTPC, i.e., 3–10 (-600
in case of thioridazine) fold hERG IC50. Bepridil, desi-
pramine, and erythromycin increased T2 in addition to
inducing beating irregularity.
In aggregate, the rat EHT responses categorized the
47 drugs in 4 groups (Fig. 8). Group 1 caused irregular
beating as the main effect (n = 5), group 2 induced a
concentration-dependent increase in T2 (n = 18). T2-
effective concentrations were 5 fold (domperidone,
disopyramide) to 100 fold FTPC (e.g., ebastine, diltia-
zem, sotalol, or moxifloxacin). Group 3 (n = 7) had
variable effects on EHT contraction including prolon-
gation of contraction time T1 (haloperidol, sertindole,
diphenhydramine, and mefloquine), shortening of T2
(terfenadine) and a decrease in force (verapamil and
astemizole). The negative inotropic effect of verapamil
a b
c d
Fig. 5 Role of IKs and IKr in rat EHTs. Statistical evaluation of
relaxation time (T2) in the presence of HMR-1556 (a), E-4031(b) or
the combination of both (c). Neither HMR-1556 nor E-4031 alone
affected T2, but the combination of both led to a marked increase of
T2 at the highest concentration (each 1 lM). d shows the concen-
tration response curves of HMR-1556, E-4031, and the combination
of both in the absence (black lines) and presence of 4AP (dashed
lines; 3 mM). In the presence of 4AP, the concentration response
curves for HMR-1556 and HMR-1556 ? E-4031 were shifted to the
left, whereas the curve for E-4031 alone was not affected. a–c each
dot stands for one analyzed EHT; *p \ 0.05 paired Student’s t test vs.
baseline (50 nM epinephrine); d n = 4–8, data are expressed as
mean ± SEM; **p \ 0.003, ***p \ 0.0001 vs. intervention ? 4AP
(#HMR-1556; *HMR-1556 ? E-4031), one-way ANOVA ? Tu-
key’s post test. Note that differences due to the presence of 4AP
were not included
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was already seen at 300 nM, approximately 4-fold
FTPC. Group 4 encompassed 17 compounds without any
effect on the parameters studied. It contained specific
IKr-blockers such as ibutilide and dofetilide, which was
in contrast to the results obtained with human EHTs
[33].
Effects of drugs under electrical pacing
Drugs which caused prolongations of T2 also reduced
beating rate in the bursts in many cases (Supplemental
Fig. 4), raising the question which effect is the cause and
which the consequence. We therefore measured EHT
contractility under continuous electrical stimulation and
perfusion and carefully evaluated the time course of the
effects of quinidine (100 lM) and erythromycin (1 mM;
Supplemental Fig. 5). Quinidine first induced a marked,
time-dependent prolongation of T2 and a reduction in
force, which was then followed by the development of a
slower rhythm independent of pacing. Erythromycin also
first prolonged T2, reduced force and then induced an
autonomous chaotic contraction pattern. Effects of both
drugs were fully reversible after washout. The data sug-
gest that the drugs exert primary effects on processes
underlying relaxation and that slowing of rate is a
consequence.
Screening of new chemical entities (NCEs)
under spontaneous beating
To get a rough estimate of the frequency of rat EHT effects
in a non-selected group of drugs a chemical library was
analyzed. NCEs were purchased from Maybridge and




Fig. 6 Effects of class I–III (Redfern) drugs on rat EHT relaxation
time (T2). a Shows the effect of antiarrhythmics (class I), b of drugs
which were withdrawn from the market (class II) and c of drugs with
measureable incidence of TdP. Each symbol reflects one analyzed
EHT. Different concentrations are indicated by different symbols
(baseline , 19 , 109 , 1009 FTPC). Statistically significant
changes in T2 are indicated by an asterisk behind the drug name.
Effects other than T2 prolongations are indicated by hashtag (e.g.,
thioridazine: irregular beating). Data are expressed as percent of
baseline (50 nM epinephrine). *p \ 0.05 paired Student’s t test vs.
baseline and at least 15 % difference between means
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NCEs were tested at 0.1, 1, and 10 lM. Most NCEs had no
effect on EHT contractility. Three NCEs prolonged T2 and
one reduced force. In two additional cases EHTs stopped
beating and didn’t react to electrical pacing (Supplemental
Table 2). Overall, an effect on EHT contractility was
observed in 21 % of the investigated NCEs.
Discussion
Assessing the proarrhythmic risks of drugs remains a
challenge in preclinical drug development. Current exper-
imental models in preclinical toxicology determine the
effect of NCEs on ion channels commonly involved in
arrhythmogenic drug effects, particularly hERG channels
[39], on electrophysiological surrogates of arrhythmias
such as triangulation in Langendorff-perfused rabbit hearts
[23, 24], on action potential duration in rabbit Purkinje
fibers [15] or the QTc intervall in telemetrically surveyed
dogs [13]. Newer models with higher throughput and/or a
human cardiomyocyte context include measurements of
heart rate in zebrafish [27], of Ca2? transients in isolated
guinea-pig [30] or human pluripotent stem cell (hPSC)-
derived cardiomyocytes [5] or of electric field potentials in
hPSC-cardiomyocytes [2]. The present study in rat EHTs
is, to the best of our knowledge, the largest head-to-head
comparison of proarrhythmic drugs performed so far. It
showed that time of relaxation (T2) in rat EHTs is essen-
tially insensitive to selective blockers of IKr or IKs, but
prolonged by inhibition of Ito, combined full inhibition of
IKr and IKs or combined inhibition of IKs and Ito. This
suggests that rat EHTs monitor mainly Ito and IKs effects of
drugs. The Ito-blocker 4AP also prolonged action potential
duration and Ca2? transients at T2-effective concentra-
tions, indicating that, in this experimental model, T2 pro-
longation follow similar prolongations of repolarization
and Ca2? transients. The data suggest that, for drug
screening purposes, T2 is a useful surrogate for time of
repolarization in rat EHTs. The high percentage of known
proarrhythmic drugs that induced concentration-dependent
T2 prolongations, aftercontractions and/or irregular beating
(group 1 and 2, 23/38 = 61 %) indicates that many clini-
cally used drugs possess effects on Ito and/or IKs in addition
to their well-characterized inhibitory action of IKr (hERG).
Characterization of rat EHTs as a test system for testing
proarrhythmic drugs
The underlying hypothesis of this study was that repolar-
ization-inhibiting drugs prolong action potential duration
a 
b
Fig. 7 Effects of class IV–V
(Redfern) drugs on rat EHT
relaxation time (T2). a Shows
the effect of drugs with isolated
reports of TdP (class IV) and
b with no reports of TdP in
humans (class V). Each symbol
reflects one analyzed EHT.
Different concentrations are
indicated by different symbols
(baseline , 19 , 109 ,
1009 FTPC). Statistical
significant changes in T2 are
indicated by an asterisk behind
the drug name. Effects other
than T2 prolongations are
indicated by hashtag (e.g.,
verapamil: negative inotropic
effect). Data are expressed as
percent of baseline (50 nM
epinephrine). *p \ 0.05 paired
Student’s t test vs. baseline and
at least 15 % difference
between means
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Fig. 8 Grouping of drugs according to the type and the concentra-
tion-dependence of the effects on EHTs. All drugs were tested in 19,
109, and 1009 free therapeutic plasma concentration (FTPC) in the
presence of 50 nM epinephrine. The absolute concentration range is
indicated in the first row. Group 1 encompasses drugs (red) that
induced polymorphic arrhythmias, group 2 (orange) prolongations of
relaxation (T2), group 3 prolongations of contraction (T1, yellow),
shortening of T2 (blue), or negative inotropic effects (violet). Group 4
(white) drugs exerted no significant effect. The colored bars in group
1–3 range from the lowest tested concentration in which the indicated
effect occurred (generally 10–1009 FTPC) to 3 mM, regardless of
whether this concentration has been tested. The white bars in group 4
indicate the tested concentration range. Also, indicated are hERG/IKr
lowest published IC50 upward ; lowest published IC50 values on
Ito upward ; lowest published IC50 values on IKs upward ;
concentrations associated with 10–20 % increases in APD90 ;
with decreases in APD90 ; QTc-prolongation in vivo ;
increased QTc in humans; estimated plasma concentration (ep) for
TdP case reports in humans ; ep for TdP case reports in combination
with other drugs/diseases ; ep for TdP case reports in combination
with a cytochrom P450 inhibitor ; ep for TdP case reports in
children ; ep QTc case reports ; asterisk TdP in humans known;
double asterisk other types of arrhythmias in humans known. The
type of depiction and most information independent of EHTs were
adopted from Redfern et al. (2003). Case reports (indicated by
asterisk), estimated plasma concentration and IC50 values on Ito/IKs
were obtained by a literature search
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and Ca2? influx and thereby time of relaxation, a parameter
easily assessable in EHT. EHTs are engineered three-
dimensional cardiac tissue constructs in which cardiac cells
are embedded in a fibrin matrix and, over 10–14 days, form
a highly organized longitudinally oriented network [16].
The 24-well mini-EHTs system is designed for a robust,
automated measurement of spontaneous or electrically
stimulated contractile activity at a medium throughput
scale. It is stable for weeks and has the advantage that
measurements can be done at near-physiological condi-
tions: 37 C, steady state beating (not dying preparations
such as isolated myocytes, papillary muscles, Purkinje
fibers, and Langendorff hearts), auxotonically work-per-
forming heart muscle constructs, and absence of invasive
experimental interventions (e.g., patch clamp or micro-
electrodes). On the other hand, it is not well suited for
measuring effects of drugs on action potentials, field
potentials, or ion channels directly. We therefore per-
formed several experiments to evaluate whether the
relaxation time T2 is indeed a suitable surrogate of time of
repolarization.
The following observations favor this assumption. (1)
T2 is easily determined and highly reproducible (11 % SD,
0.77 % SEM, n = 221). (2) The duration of contraction
and relaxation corresponds well with that of action poten-
tials in rat EHTs and both were prolonged in the presence
of 4AP as well as quinidine. Action potential duration
(APD90) measured with sharp microelectrodes at 36 C
amounted to a mean of 113 ms, time to 90 % Ca2? return
to a mean of 124 ms at 37 C, and T1 ? T2 (at 80 %
relaxation) amounted to a mean of 159 ms at 37 C (this
study and [16]). Thus, it is reasonable to assume that
prolongations of repolarization affect T2. (3) Drugs with
well-characterized actions on Ito [41], IKr [43], and IKs [36]
had reproducible, concentration-dependent and reversible
effects on T2. 4AP started to prolong T2 at 3 mM, which
corresponds to 3-fold IC50 in adult rat cardiac myocytes
[41] and confirms the prominent role of Ito for rodent heart
repolarization [19]. The lack of effect of E-4031, dofeti-
lide, ibutilide, and HMR-1556 even at 100-fold IC50 con-
centrations confirms the minor role of IKr and IKs for
repolarization in rat cardiac myocytes [29]. Interestingly,
however, the combined application of high concentrations
of E-4031 and HMR-1556 markedly prolonged T2. Given
the high selectivity of both drugs for IKr and IKs [36, 41],
respectively, the data suggest that IKr and IKs can substitute
for each other, but together play a role for repolarization in
rat EHTs. The strong effect of HMR-1556 in the presence
of 3 mM 4AP (and the lack of an E-4031 effect under this
condition) suggests a greater role for IKs than IKr. The
necessary channel subunits are expressed in rat EHTs
(KCNH2a, KCNQ1a, and KCNE1/E2 mRNAs are present
in rat EHTs [16]).
Whereas all this argues for repolarization as an impor-
tant parameter of relaxation time T2 in our system, it is
obvious that other mechanisms have to be considered and
that T2 prolongations alone do not prove effects on repo-
larization. Any effect on beating rate will affect T2 because
of the well-known frequency-dependent acceleration of
relaxation. Such effect could be excluded in case of quin-
idine and erythromycin (Supplemental Fig. 5), but may
play a role in other cases. Drugs that directly affect intra-
cellular Ca2? handling could alter T2 independently of
repolarization. Indeed, caffeine at a high concentration
(5 mM) which enhances the open probability of RyR2
reduced beating rate and caused widening of contraction
twitches (Supplemental Fig. 1). Thapsigargin, a selective
inhibitor of SERCA, did not affect time of relaxation as
such (3–30 nM), but aggravated the relaxation-slowing
effect of 4AP (Supplemental Fig. 2). Another possibility to
affect T2 independently of repolarization is an effect on
myofilament Ca2? sensitivity. Ca2? sensitizers such as
EMD 57033 [34] shift the force-pCa curve to the left and
thereby prolong relaxation as recently shown in mouse
EHTs [35]. The unexpected T2-prolongation under diltia-
zem may represent this mechanism. A study in isolated
adult rat ventricular myocytes reported a mild myofilament
Ca2? sensitizing effect of diltiazem [9]. Such an effect may
also explain the unexpected lack of significant negative
inotropic effects of this compound at the highest tested
concentration (10 lM) which was in contrast to verapamil.
Conversely, epinephrine (Supplemental Fig. 3) and all
other cAMP-dependent drugs increase the PKA-dependent
phosphorylation of troponin I, myosin binding protein C
and others and shift the curve to the right. This favors
relaxation and abbreviates T2. Taken together, T2-prolon-
gation of rat EHTs can be caused not only by blockers of
repolarization (mainly Ito, IKs, very little contribution of
IKr), but also rate-slowing drugs, Ca
2? sensitizers or
blockers of cAMP-dependent pathways such as carbachol
(Supplemental Fig. 3), which needs to be considered in
drug screening efforts.
The pronounced prolongation of relaxation at high
concentrations of 4AP and aftercontractions were sensitive
to both SEA0400 and JTV519 (Fig. 4), but relaxation
remained significantly prolonged in their presence
(*200 %). This finding is interesting as it suggests that the
primary effect of 4AP, the inhibition of repolarization, has
time-dependent (see time course in Fig. 4) secondary
effects that affect time of relaxation. Very likely, this
secondary effect corresponds to increased filling of the SR
with Ca2? with the final consequence of RyR2-mediated
spontaneous Ca2? release and NCX-mediated Ca2? extru-
sion. The latter transport is electrogenic and contributes to
prolonged depolarization and after depolarizations, visible
in our system as marked prolongations of T2 and
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123
aftercontractions. An interesting speculation is that group 1
(Fig. 8) drugs directly interfere with RyR2 and/or NCX or
SR function and therefore induce irregular beating,
whereas group 2 drugs primarily affect repolarization and
therefore prolong T2 before causing extra beats. On the
other side, group 1 and 2 effects cannot be firmly separated
because three group 1 drugs also caused T2 prolongations.
Interestingly, tetracaine (also flecainide (0.5 lM); data not
shown) did not mimic the effect of JTV519 (Supplemental
Fig. 2), although both have inhibitory effects on RyR2-
mediated Ca2? release [18, 40]. Possibly, their main effect
on INa which is not shared by JTV519 could explain the
difference.
Drug-induced relaxation slowing and beating
irregularities in rat EHTs
We selected drugs according to a list published by Redfern
and colleagues [31] that grouped drugs according to their
proarrhythmic potential. 15/33 drugs with various degree
of risk for TdP (Class I–IV) showed T2 prolongation or
beating irregularities in our system (group 1 and 2). The
percentage did not clearly differ between those that were
withdrawn from the market for TdP (1/5) and those with
only isolated TdP reports (6/13). In addition, T2-prolon-
gation was observed in 6/14 drugs considered safe. This
clearly indicates that the rat EHTs test does not sufficiently
discriminate between high and low risk drugs, very likely
due to the lack of IKr sensitivity.
Nevertheless, screening the large number of drugs
revealed a number of interesting novel informations. (1) It
is apparent that T2 prolongations and beating irregularities
were seen mainly in those drugs which reach high FTPC in
clinical use and were therefore tested at high absolute
concentrations (compare concentration range of Group 1
and 2 drugs with group 3 and 4; Fig. 8). This confirms the
general rule in pharmacology that drugs with low potency
at their target have a higher chance of off-target toxicity
than high affinity drugs. (2) Most effects were seen at
30–100-fold FTPC and higher. This is at the upper limit
generally considered a critical safety margin [31] and point
to a relatively low sensitivity of our assay. Rather than
indicating simple non-specific effects (drugs such as se-
matilide and ciprofloxacin were tested at up to 300 lM) the
data with E-4031, HMR-1556 and 4AP indicate that almost
complete block of one or more currents is required to
overcome safety mechanisms of repolarization in a rela-
tively intact system such as the EHT. As such, the low
sensitivity probably reflects the situation in vivo better than
isolated cells [28]. Pharmacokinetic peculiarities and time-
dependent effects likely add to high concentration
requirements. For example, amiodarone is very lipophilic
and accumulates in cells over time. With an apparent
volume of distribution of 20–200 l/kg, the low FTPC of
amiodarone (0.3 nM) is orders of magnitude lower than
cellular concentrations in the steady state. (3) Concentra-
tions in which group 1 and 2 drugs exerted their effects on
EHTs were generally well above their IC50 for hERG (gray
bars in Fig. 8). Notable exceptions are domperidone and
phenytoin, where relaxation slowing occurred at concen-
trations below hERG IC50. Since E-4031 at high concen-
tration markedly potentiated the effect of HMR-1556
without having an effect alone, the data suggest that inhi-
bition of IKr may participate in the effect of group 1 and 2
drugs, but is not sufficient to fully explain them. Inhibition
of other currents must come into play. We found reports of
Ito-inhibiting activity for 14 drugs (blue bars in Fig. 8). In
four of these (imipramine, propafenone, quinidine, and
clarithromycin) published IC50 values for hERG and Ito
were at or below the threshold for T2 prolongation or
irregularity, providing a likely mechanism of action.
Moreover, we found reports of IKs-inhibiting effects for 20
drugs (green bars in Fig. 8). In six of these cases (bepridil,
thioridazine, propafenone, quinidine, cibenzoline, and
sotalol), the IC50 was at or below the threshold for group 1
or 2 effects. It is interesting that quinidine at the T2-
threshold concentration (100 lM) inhibits all three currents
IKr, Ito, and IKs. Other currents involved in rat cardiac
repolarization such as IK1, Iss, and IKx [19] or IKATP [4] and
IKNa are also potential targets, but not much is known about
effects of the drugs investigated. Taken together, the data
indicate that many clinically used drugs, some of them
associated with TdP, others not, inhibit cardiac repolarizing
currents in addition to IKr. This supports recent data sug-
gesting that combined channel block underlies clinical
proarrhythmia [28].
Miscellaneous effects on EHT function
Some drugs caused T1 prolongations (haloperidol, sertin-
dole, diphenhydramine, and mefloquine), T2 acceleration
(terfenadine) or negative inotropic effects (verapamil).
Whereas the latter is the expected main effect of the drug,
the mechanism of the other is unclear at present. T1 pro-
longations could indicate reduced conduction velocity in
the EHT, a typical consequence of INa inhibition. However,
pure INa blockers such as TTX or lidocaine did not prolong
T1 (data not shown), arguing against this idea. An alter-
native may be an effect on gap junction conduction. At
least mefloquine is known to inhibit numerous connexins
(C9), including C 9 43 [8]. T2 shortening could be due to
accelerated repolarization by stimulation of K-currents or
accelerated myofilament relaxation, but also due to an
inhibition of INa. In fact, terfenadine, which also shortened
action potential duration in the SCREENIT test system
(10 lM [23]), has recently been suggested to cause
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arrhythmias not by a TdP mechanism, but by its strong INa-
blocking activity [46].
Taken together, rat EHTs are not suitable as a general
screening assay for proarrhythmic drug effects due to the
small contribution of IKr for rat EHT repolarization. On the
other hand, the assay is a simple and robust system for the
analysis of non-hERG-related drug effects on cardiac
function. Relaxation time was shown to be a particularly
suited screening parameter, sensitive to drugs affecting
cardiac repolarization, but also Ca2? handling or myofila-
ment function. The high fraction of drugs with known
arrhythmogenic effects that prolonged relaxation or
induced irregular beating in this hERG-insensitive system
suggest that Ito and IKs effects add to the proarrhythmic risk
of drugs and require further consideration.
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